NCT01145053已完成不适用
Long Time Survey of RESPIMAT in Daily Clinical Use
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 361
- 主要终点
- Incidence of Adverse Events (AEs)
研究概览
简要总结
To investigate safety and effectiveness information on the use of Tiotropium Respimat for long time of period in daily practical clinical circumstances, and to obtain proper drug use information.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Incidence of Adverse Events (AEs)
时间窗: Week 52
The number of patient with any AEs, patients with drug-related AEs
次要结局
- Amount of Sputum(Week 0 and Week 52)
- Nocturnal Sleep(Week 0 and Week 52)
- Effectiveness(Week 52)
- Forced Expiratory Volume in One Second (FEV1)(Week 0 and Week 52)
- Cough Frequency(Week 0 and Week 52)
- Shortness of Breath(Week 0 and Week 52)
研究者
相似试验
已完成
3 期
Tiotropium / Respimat One-Year StudyPulmonary Disease, Chronic ObstructiveNCT00168831Boehringer Ingelheim1,007
已完成
3 期
Tiotropium / Respimat One-Year StudyPulmonary Disease, Chronic ObstructiveNCT00168844Boehringer Ingelheim983
已完成
3 期
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind TrialEpilepsyNCT00310375GlaxoSmithKline181
已完成
不适用
Impact of Tiotropium Add-on Therapy in Patients With AsthmaAsthmaNCT03964220Boehringer Ingelheim7,857
已完成
3 期
Tiotropium / Respimat One Year Study in COPD.Pulmonary Disease, Chronic ObstructiveNCT00387088Boehringer Ingelheim3,991